Aurora Cannabis (ACB) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the Lead Independent Director, with formal appointments of recording secretary and scrutineer for a virtual-only format.

• Voting procedures explained, with all resolutions open for polling simultaneously and no real-time interventions during formal proceedings.

• Notice-and-access procedures confirmed, with quorum achieved at 26.86% of outstanding shares represented by proxy.

Financial performance review

• Fiscal 2026 net revenue rose 11% to CAD 321 million, exceeding guidance by CAD 8 million, with 55% generated outside Canada.

• Adjusted EBITDA grew 32% year-over-year to CAD 54 million; adjusted gross margin increased to 64%.

• Adjusted net income improved by over CAD 12 million; year-end cash position was CAD 165 million with no debt.

• Q1 2027 net revenue was CAD 67.6 million, with international medical cannabis revenue up 17% to CAD 43 million.

Board and executive committee updates

• Number of directors fixed at five for the ensuing year; all management nominees elected as directors.

• EY reappointed as auditor for the ensuing year.